IMARC Group’s report titled “In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2024–2032”. The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024–2032.

Grab a sample PDF of this report: https://www.imarcgroup.com/in-vivo-cro-market/requestsample

Factors Affecting the Growth of the In-Vivo CRO Industry:

● Technological Advancements and Integration:

The adoption of technologies, such as artificial intelligence (AI), machine learning (ML), and advanced imaging techniques, are revolutionizing in-vivo studies, enhancing the accuracy and efficiency of data collection and analysis. These technologies enable more precise modeling of diseases, better prediction of drug efficacy and safety, and more robust data management systems. In-vivo contract research organizations (CROs) are at the forefront of incorporating these technologies into their service offerings, providing their clients with cutting-edge solutions that streamline the research process. Additionally, the integration of digital tools and platforms facilitates improved collaboration between CROs and their clients, ensuring seamless communication and project management.

● Rising Demand for Personalized Medicine:

The growing demand for personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic, biomarker, and phenotypic information, is positively influencing the market. This approach requires extensive in-vivo testing to understand the interactions between treatments and specific biological markers. CROs play a crucial role in conducting these specialized studies, which often involve complex protocols and advanced technologies. The move towards personalized medicine necessitates more detailed and patient-specific data, which CROs are well-equipped to provide through their expertise and state-of-the-art facilities.

● Increasing Regulatory Stringency:

Regulatory bodies worldwide are implementing more rigorous standards for drug and medical device approvals to ensure patient safety and efficacy. This regulatory environment necessitates thorough and meticulous in-vivo testing to meet the stringent requirements. CROs are adept at navigating these complex regulatory landscapes, providing comprehensive testing services that adhere to the highest standards. Their expertise in regulatory compliance helps pharmaceutical and biotech companies avoid costly delays and ensure their products meet all necessary criteria. The continuous updates and tightening of regulatory frameworks underscore the importance of high-quality in-vivo studies, making CROs indispensable partners for companies aiming to achieve timely and successful product approvals.

Leading Companies Operating in the Global In-Vivo CRO Market Industry:

• Charles River Laboratories International Inc.
• Evotec SE
• ICON plc
• Iris Pharma (Abionyx Pharma)
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• North American Science Associates LLC
• Parexel International Corporation
• Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
• Pronexus Analytical AB
• Syneos Health
• WuXi AppTec.

In-Vivo CRO Market Report Segmentation:

By Type:

• Rodent
• Rats
• Mice
• Others
• Non-Rodent

Rodent (rats, mice, and others) exhibits a clear dominance in the market due to the similarity in genetic makeup to humans, rapid reproduction rates, and well-established use in biomedical research.

By GLP Type:

• Non-GLP
• In House
• Outsourcing
• GLP Toxicology
• In House
• Outsourcing

GLP toxicology (in house and outsourcing) represents the largest segment, as it is critical for assessing the safety and potential adverse effects of new drugs.

By Indications:

• Autoimmune/Inflammation Conditions
• Rheumatoid Arthritis
• Multiple Sclerosis
• Osteoarthritis
• Irritable Bowel Syndrome
• Others
• Pain Management
• Chronic Pain
• Acute Pain
• Oncology
• Blood Cancer
• Solid Tumor
• Others
• CNS Conditions
• Epilepsy
• Parkinson’s Disease
• Huntington’s Disease
• Stroke
• Traumatic Brain Injury
• ALS
• Muscle Regeneration
• Others
• Diabetes
• Obesity
• Others

Oncology (blood cancer, solid tumor, and others) holds the biggest market share, driven by the high prevalence of cancer and the growing investment in developing new cancer therapies.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the market owing to its advanced research infrastructure, rising funding for life sciences, and presence of major pharmaceutical and biotechnology companies.

Global In-Vivo CRO Market Trends:

The growing emphasis on translational research, which aims to bridge the gap between laboratory discoveries and clinical applications, is offering a favorable market outlook. This approach involves integrating preclinical and clinical research to accelerate the development of new therapies. In-vivo CROs are adopting translational research methodologies to provide more comprehensive and predictive data that can enhance the efficiency and success rate of clinical trials.

Additionally, the integration of advanced data analytics and bioinformatics to improve functionality is bolstering the market growth. By leveraging big data and sophisticated analytical tools, CROs can offer deeper insights into disease mechanisms, treatment efficacy, and patient responses. This data-driven approach not only improves the precision of in-vivo studies but also supports personalized medicine initiatives.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145 | United Kingdom: +44–753–713–2163